MGI Pharma Files Aquavan NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.
You may also be interested in...
FDA Rejects Eisai’s Aquavan Injection
Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.
FDA Rejects Eisai’s Aquavan Injection
Advisory panel had voted in favor of propofol prodrug, with conditions; timeline for sedative’s resubmission is uncertain.
Committee To Probe Dosing Of MGI's Aquavan
May 7 agenda will look into providers untrained in anesthesia, too.